Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Correspondence] Ovarian cancer screening: UKCTOCS trial

UKCTOCS (March 5, p 945)1 was an expensive (£17 million), well designed, and well executed screening trial with a solid and convincing negative conclusion based on its previous primary endpoints. It was surprising that the peer reviewers allowed the authors to include the secondary data-driven analysis (excluding prevalent cases) in the main trial report. But it was shocking that the Lancet Editors allowed this secondary post-hoc analysis to be included in the abstract and in the press release. The absence of difference in all-cause mortality was reported only in the appendix.